Integrative Cardiac Health/Military Cardiovascular Outcomes Research
Abstract
USU is a “central focal point for health-related education and training, research and scholarship, and leadership support to operational military units around the world” and is the ideal engine to establish a strategic partnership to address cardiovascular health. FY2021 Accomplishments (Selected): The MiCOR portfolio currently includes 19 total studies with two broad themes: 1. Prevention of cardiac events in ADSM (16 projects) 2. Evaluating cardiac impact of COVID-19 infection/vaccination (3 Projects) Major landmarks: - 5400 USNA midshipmen screened using novel electrocardiographic device in support of BUMED Sudden Cardiac Death Risk Assessment Project Authorization Letter. Serious cardiac abnormalities were identified in 0.46%. Cited in HASC preamble to NDAA for extension to other academies. Briefing Accessions Medical Standards Working Group scheduled for December 2021 to add enhanced cardiac screening to MEPS and DODMERB recruit screening, affecting 150,000 recruits annually. - Long Term Outcomes following Combat Injury- Retrospectively compared CV outcomes in 17,570 warfighters and demonstrated that combat injury is associated with significant increases in cardiac arrhythmias, hypertension, diabetes mellitus, and coronary artery disease. Additional grant funding from CDMRP for a prospective study sought; decision anticipated January 2022. -Peer-reviewed Papers Published: 56 -Books: 1 -Book Chapters: 7 -Invited Presentations: 5 -Scientific Conference Workshops/Panels: 4 -Scientific Conference Paper/Poster Presentations: 20 -Four studies completed enrolment in FY21 and are in final analysis. - Six studies in active enrollment. -Long Haul COVID randomized clinical trial of ivabradine in institutional review. -1,000,000 USAF EKGs transferred to DHA and currently under analysis for machine learning. -Sleep Disordered Breathing- Analysis of opioids and their impact on sleep disordered breathing has been completed and published. Analysis of the QT interval variability as the mortality predictor is 50% completed since January 2021. Expected completion Q4 FY2022.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2023
- Source ID
- ccb2273659433167e4f2ea31698b9ba5